Phaseline

Companies › Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tulisokibart (MK-7240/PRA023)
IL-18 receptor antagonist
IL-18R1Phase 2Diffuse Cutaneous Systemic SclerosisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05270668Tulisokibart (MK-7240/PRA023)Phase 2Diffuse Cutaneous Systemic SclerosisImmunologyNov 2026

Targets

IL-18R1 (1)

Companies with the same targets

–

Companies built like this

RAPT Therapeutics, Inc., a member of the GSK plc group of companies AnaptysBio Q32 Bio Chengdu Kangnuoxing Biopharma Ashibio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.